Marc Goodman
Stock Analyst at Leerink Partners
(3.48)
# 973
Out of 4,415 analysts
82
Total ratings
50%
Success rate
17.47%
Average return
Main Sectors:
27 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LENZ LENZ Therapeutics | Initiates: Outperform | $32 | $16.46 | +94.41% | 1 | Apr 15, 2024 | |
| AMLX Amylyx Pharmaceuticals | Downgrades: Market Perform | n/a | $2.03 | - | 4 | Mar 11, 2024 | |
| BLTE Belite Bio | Initiates: Outperform | $25 | $43.20 | -42.13% | 1 | Jul 26, 2023 | |
| DNLI Denali Therapeutics | Initiates: Outperform | $50 | $17.14 | +191.72% | 1 | Jan 30, 2023 | |
| BHVN Biohaven Pharmaceutical Holding Company | Initiates: Outperform | $24 | $40.69 | -41.02% | 4 | Jan 24, 2023 | |
| RLMD Relmada Therapeutics | Maintains: Outperform | $42 → $10 | $3.68 | +171.74% | 2 | Jan 23, 2023 | |
| MRNS Marinus Pharmaceuticals | Maintains: Outperform | $27 → $23 | $1.51 | +1,423.18% | 4 | Jan 23, 2023 | |
| EOLS Evolus | Maintains: Outperform | $18 → $20 | $13.30 | +50.38% | 2 | Jan 19, 2023 | |
| AXSM Axsome Therapeutics | Maintains: Outperform | $65 → $85 | $74.80 | +13.64% | 5 | Nov 29, 2022 | |
| NBIX Neurocrine Biosciences | Maintains: Market Perform | $100 → $115 | $140.71 | -18.27% | 3 | Nov 2, 2022 | |
| BIIB Biogen | Maintains: Outperform | $270 → $310 | $217.51 | +42.52% | 10 | Oct 26, 2022 | |
| ELYM Eliem Therapeutics | Maintains: Outperform | $9 → $4 | $10.16 | -60.61% | 4 | Aug 16, 2022 | |
| AVDL Avadel Pharmaceuticals | Maintains: Outperform | $6 → $12 | $18.82 | -36.24% | 2 | Aug 11, 2022 | |
| XENE Xenon Pharmaceuticals | Maintains: Outperform | $40 → $46 | $43.00 | +6.98% | 4 | Aug 11, 2022 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Outperform | $27 → $21 | $17.05 | +23.17% | 3 | Aug 9, 2022 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Outperform | $200 → $210 | $110.01 | +90.89% | 5 | Aug 4, 2022 | |
| SAGE Sage Therapeutics | Maintains: Market Perform | $50 → $40 | $13.94 | +186.94% | 4 | Jul 11, 2022 | |
| ACIU AC Immune | Maintains: Outperform | $15 → $10 | $2.44 | +309.84% | 2 | Jul 11, 2022 | |
| ALKS Alkermes | Maintains: Market Perform | $24 → $27 | $24.05 | +12.27% | 4 | Apr 28, 2022 | |
| OPT Opthea | Initiates: Outperform | $25 | $3.32 | +653.01% | 1 | Apr 26, 2022 | |
| ITCI Intra-Cellular Therapies | Maintains: Outperform | $65 → $70 | $68.80 | +1.74% | 3 | Apr 21, 2022 | |
| ALDX Aldeyra Therapeutics | Maintains: Outperform | $24 → $15 | $4.21 | +256.29% | 2 | Dec 21, 2021 | |
| ABBV AbbVie | Assumes: Neutral | n/a | $163.79 | - | 3 | Jan 23, 2019 | |
| ULTA Ulta Beauty | Maintains: Buy | n/a | $397.39 | - | 3 | Dec 7, 2018 | |
| BMY Bristol-Myers Squibb Company | Downgrades: Neutral | n/a | $43.99 | - | 2 | May 21, 2018 | |
| MRK Merck & Co. | Maintains: Buy | n/a | $127.51 | - | 2 | Oct 30, 2017 | |
| PRGO Perrigo Company | Maintains: Buy | n/a | $32.79 | - | 1 | Oct 5, 2017 |
LENZ Therapeutics
Apr 15, 2024
Initiates: Outperform
Price Target: $32
Current: $16.46
Upside: +94.41%
Amylyx Pharmaceuticals
Mar 11, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $2.03
Upside: -
Belite Bio
Jul 26, 2023
Initiates: Outperform
Price Target: $25
Current: $43.20
Upside: -42.13%
Denali Therapeutics
Jan 30, 2023
Initiates: Outperform
Price Target: $50
Current: $17.14
Upside: +191.72%
Biohaven Pharmaceutical Holding Company
Jan 24, 2023
Initiates: Outperform
Price Target: $24
Current: $40.69
Upside: -41.02%
Relmada Therapeutics
Jan 23, 2023
Maintains: Outperform
Price Target: $42 → $10
Current: $3.68
Upside: +171.74%
Marinus Pharmaceuticals
Jan 23, 2023
Maintains: Outperform
Price Target: $27 → $23
Current: $1.51
Upside: +1,423.18%
Evolus
Jan 19, 2023
Maintains: Outperform
Price Target: $18 → $20
Current: $13.30
Upside: +50.38%
Axsome Therapeutics
Nov 29, 2022
Maintains: Outperform
Price Target: $65 → $85
Current: $74.80
Upside: +13.64%
Neurocrine Biosciences
Nov 2, 2022
Maintains: Market Perform
Price Target: $100 → $115
Current: $140.71
Upside: -18.27%
Biogen
Oct 26, 2022
Maintains: Outperform
Price Target: $270 → $310
Current: $217.51
Upside: +42.52%
Eliem Therapeutics
Aug 16, 2022
Maintains: Outperform
Price Target: $9 → $4
Current: $10.16
Upside: -60.61%
Avadel Pharmaceuticals
Aug 11, 2022
Maintains: Outperform
Price Target: $6 → $12
Current: $18.82
Upside: -36.24%
Xenon Pharmaceuticals
Aug 11, 2022
Maintains: Outperform
Price Target: $40 → $46
Current: $43.00
Upside: +6.98%
ACADIA Pharmaceuticals
Aug 9, 2022
Maintains: Outperform
Price Target: $27 → $21
Current: $17.05
Upside: +23.17%
Jazz Pharmaceuticals
Aug 4, 2022
Maintains: Outperform
Price Target: $200 → $210
Current: $110.01
Upside: +90.89%
Sage Therapeutics
Jul 11, 2022
Maintains: Market Perform
Price Target: $50 → $40
Current: $13.94
Upside: +186.94%
AC Immune
Jul 11, 2022
Maintains: Outperform
Price Target: $15 → $10
Current: $2.44
Upside: +309.84%
Alkermes
Apr 28, 2022
Maintains: Market Perform
Price Target: $24 → $27
Current: $24.05
Upside: +12.27%
Opthea
Apr 26, 2022
Initiates: Outperform
Price Target: $25
Current: $3.32
Upside: +653.01%
Intra-Cellular Therapies
Apr 21, 2022
Maintains: Outperform
Price Target: $65 → $70
Current: $68.80
Upside: +1.74%
Aldeyra Therapeutics
Dec 21, 2021
Maintains: Outperform
Price Target: $24 → $15
Current: $4.21
Upside: +256.29%
AbbVie
Jan 23, 2019
Assumes: Neutral
Price Target: n/a
Current: $163.79
Upside: -
Ulta Beauty
Dec 7, 2018
Maintains: Buy
Price Target: n/a
Current: $397.39
Upside: -
Bristol-Myers Squibb Company
May 21, 2018
Downgrades: Neutral
Price Target: n/a
Current: $43.99
Upside: -
Merck & Co.
Oct 30, 2017
Maintains: Buy
Price Target: n/a
Current: $127.51
Upside: -
Perrigo Company
Oct 5, 2017
Maintains: Buy
Price Target: n/a
Current: $32.79
Upside: -